Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer - PubMed (original) (raw)

Clinical Trial

. 2012 Mar 15;18(6):1798-807.

doi: 10.1158/1078-0432.CCR-11-2094. Epub 2012 Mar 1.

Richard Fisher, Kelly S Oliner, Richard J Young, Hongbin Cao, Christina Kong, Edward Graves, Rodney J Hicks, Grant A McArthur, Lester Peters, Brian O'Sullivan, Amato Giaccia, Danny Rischin

Affiliations

Clinical Trial

Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer

Quynh-Thu Le et al. Clin Cancer Res. 2012.

Abstract

Purpose: Hepatocyte growth factor (HGF) is a hypoxia-induced secreted protein that binds to cMet and regulates interleukin (IL)-8 expression. We evaluated the role of circulating HGF and IL-8 as prognostic and predictive factors for efficacy of tirapazamine (TPZ), a hypoxic cell cytotoxin.

Experimental design: Patients with stages III to IV head and neck cancer were randomized to receive radiotherapy with cisplatin (CIS) or CIS plus TPZ (TPZ/CIS). Eligibility for the substudy included plasma sample availability for HGF and IL-8 assay by ELISA and no major radiation deviations (N = 498). Analyses included adjustment for major prognostic factors. p16(INK4A) staining (human papillomavirus surrogate) was carried out on available tumors. Thirty-nine patients had hypoxia imaging with (18)F-fluoroazomycin arabinoside ((18)FAZA)-positron emission tomography.

Results: Elevated IL-8 level was associated with worse overall survival (OS) irrespective of treatment. There was an interaction between HGF and treatment arm (P = 0.053); elevated HGF was associated with worse OS in the control but not in the TPZ/CIS arm. Similar trends were observed in analyses restricted to p16(INK4A)-negative patients. Four subgroups defined by high and low HGF/IL-8 levels were examined for TPZ effect; the test for interaction with arm was P = 0.099. TPZ/CIS seemed to be beneficial for patients with high HGF and IL-8 but adverse for low HGF and high IL-8. Only HGF correlated with (18)FAZA tumor standard uptake value.

Conclusions: IL-8 is an independent prognostic factor irrespective of treatment. There is an interaction between HGF and treatment arm. Certain subgroups based on IL-8/HGF levels seemed to do better with TPZ/CIS while others did worse, highlighting the complexity of hypoxia targeting in unselected patients.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None

Figures

Figure 1

Figure 1

Overall survival for 498 patients by pre-treatment HGF levels and treatment arm

Figure 2

Figure 2

Overall survival for 498 patients by pre-treatment IL8 levels and treatment arm

Figure 3

Figure 3

A. Interaction plot of relative risk for death (relative hazard rates, RHR, log scale) by treatment arm and IL8/HGF groups, adjusting for prognostic factors. The graph shows the RHRs rates for each of the eight combinations of treatment arm and IL8 and HGF levels, where a line joins the RHRs of CIS and TPZ/CIS arms for each IL8/HGF combination. No interaction would be indicated by all lines being parallel. The slope of each line is the log of the hazard ratio for arm (TPZ/CIS: CIS) for the given IL8/HGF subgroup. The figure suggests that OS is worse with TPZ/CIS for high IL8/low HGF patients and better for high IL8/high HGF patients, compared with CIS. B. Overall survival by treatment arm and HGF levels within the high IL8 group

Figure 3

Figure 3

A. Interaction plot of relative risk for death (relative hazard rates, RHR, log scale) by treatment arm and IL8/HGF groups, adjusting for prognostic factors. The graph shows the RHRs rates for each of the eight combinations of treatment arm and IL8 and HGF levels, where a line joins the RHRs of CIS and TPZ/CIS arms for each IL8/HGF combination. No interaction would be indicated by all lines being parallel. The slope of each line is the log of the hazard ratio for arm (TPZ/CIS: CIS) for the given IL8/HGF subgroup. The figure suggests that OS is worse with TPZ/CIS for high IL8/low HGF patients and better for high IL8/high HGF patients, compared with CIS. B. Overall survival by treatment arm and HGF levels within the high IL8 group

Similar articles

Cited by

References

    1. Le QT, Denko NC, Giaccia AJ. Hypoxic gene expression and metastasis. Cancer Metastasis Rev. 2004;23:293–310. - PubMed
    1. Le QT, Giaccia AJ. Therapeutic exploitation of the physiological and molecular genetic alterations in head and neck cancer. Clin Cancer Res. 2003;9:4287–95. - PubMed
    1. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol. 2007;25:4066–74. - PubMed
    1. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58–62. - PubMed
    1. Hill RP. Targeted treatment: insights from studies of osteopontin and hypoxia. Lancet Oncol. 2005;6:733–4. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources